The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of imatinib, cisplatin, and fluoruracil in patients with advanced gastric cancer.
Martina Mayr
No relevant relationships to disclose
Barbara Alberter
Employment or Leadership Position - Novartis
Karin Becker
No relevant relationships to disclose
Roland M. Schmid
No relevant relationships to disclose
Matthias Philip Ebert
No relevant relationships to disclose